Skip to main content
SpringerLink
Log in

Authors’ Response to Silverman and Colleagues’ Comment on “Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence”

  • Letter to the Editor
  • Published:
Drug Safety Aims and scope Submit manuscript

The Original Article was published on 28 June 2018

The Original Article was published on 28 June 2018

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Silverman B, Bloomgren G, Jain P, Marcopul K, Silveira A, Fratantonio J, et al. Comment on “Review of case narratives from fatal overdoses associated with injectable naltrexone for opioid dependence. Drug Saf. 2018. https://doi.org/10.1007/s40264-018-0691-x.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Kelty E, Hulse G. Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone. Int J Drug Policy. 2017;46:54–60.

    Article  PubMed  Google Scholar 

  3. Saxon AJ, Akerman SC, Liu C-C, Sullivan MA, Silverman BL, Vocci FJ. Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol’s Cost and Treatment Outcomes Registry. Addiction. 2018. https://doi.org/10.1111/add.14199 (Epub ahead of print).

    Article  PubMed  Google Scholar 

  4. Aklermes. Important safety information for Vivitrol®. 2018. https://www.vivitrolhcp.com/important-safety-information. Accessed 6 Jun 2018.

  5. Lee JD, Nunes EV, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309–18.

    Article  CAS  PubMed  Google Scholar 

  6. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;23(340):c869.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of North Carolina, 137 E. Franklin St. Suite 500, CB 7505, Chapel Hill, NC, 27599, USA

    Nabarun Dasgupta

  2. Open Society Foundations, New York, NY, USA

    Roxanne Saucier & Daniel Wolfe

Authors
  1. Nabarun Dasgupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roxanne Saucier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel Wolfe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nabarun Dasgupta.

Ethics declarations

Funding

No funding was received for the preparation of this letter.

Conflict of interest

Daniel Wolfe is an employee of Open Society Foundations and Roxanne Saucier is a consultant to Open Society Foundations. Nabarun Dasgupta is a part-time employee of the RADARS System, which had no involvement in this letter. The RADARS System is supported by subscriptions from pharmaceutical manufacturers, and governmental and non-governmental agencies for data, research, and reporting services. The RADARS System is the property of the Denver Health and Hospital Authority, a political subdivision of the State of Colorado (USA). Employees are prohibited from financial relationships with any biopharmaceutical company.

Additional information

This reply refers to the comment available at https://doi.org/10.1007/s40264-018-0691-x.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dasgupta, N., Saucier, R. & Wolfe, D. Authors’ Response to Silverman and Colleagues’ Comment on “Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence”. Drug Saf 41, 995–997 (2018). https://doi.org/10.1007/s40264-018-0692-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-018-0692-9

Search

Navigation